AlgiPharma awarded 16 MNOK grant from the Norwegian Research Council’s Innovation Project for the Industrial Sector program.

AlgiPharma has been awarded up to NOK 16 million from the Norwegian Research Councils Innovation Project for the Industrial Sector program for the project “Fermentation Scaleup for Manufacturing of Pharmaceutical Alginate Oligosaccharides (Algi-SCALEUP).”

The project will last for 3 years and will demonstrate commercial scale production of alginate oligomers of pharmaceutical quality through large scale cost-effective microbial fermentation with concomitant large-scale downstream processing. The project will provide AlgiPharma with an alternative source of high-grade alginates for pharmaceutical and biomedical uses, while also contributing to the stimulation of new market opportunities.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma is Recruiting – Again!

Director Clinical Research / Chief Medical Officer

AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. The deadline for applications is the 24th May 2020 (see links below for further details).

More details can be found at:

www.borka.no/jobb/director-clinical-research-chief-medical-officer/

www.finn.no/177948590

www.linkedin.com/groups/2085624

www.linkedin.com/company/borka-consulting

www.facebook.com/BorkaRekruttering

twitter.com/Borka_Pharma

www.instagram.com/borka_rekruttering/

 

New parent company in the AlgiPharma group

AlgiPharma AS acquired by AlgiPharma AB

On December 20, 2019 the Swedish AlgiPharma AB finalized the acquisition of the Norwegian AlgiPharma AS. All shareholders in AlgiPharma AS accepted the offer from AlgiPharma AB which means that the shareholders have the same number of shares and ownership percentage in the new parent company AlgiPharma AB as they previously had in AlgiPharma AS. Most of the operations will continue to be run in the Norwegian subsidiary AlgiPharma AS.

AlgiPharma appoints new CFO

AlgiPharma appoints Fredrik Alpsten as new Chief Financial Officer (CFO)

Mr Alpsten has an MSc degree from Stockholm School of Economics. He has 25 years of operational, financial, and strategic business experience as an executive in the life science field. He has served as Senior Vice President and CFO of Boule Diagnostics AB, a Swedish publicly-traded diagnostics company. During his time at Boule, he also served as President and CEO of Clinical Diagnostic Solutions Inc., a US subsidiary of Boule. He has also been CFO and Deputy CEO of IRRAS AB, a Swedish listed med-tech company and President and CEO of Doxa AB, a Swedish publicly-traded medical technology company. He currently serves as Chairman of the Board of Personlig Almanacka Nordic AB. He is also a board member and chairman of the audit committee of Binero Group AB (listed at Nasdaq) and board member of Pharmetheus AB.

AlgiPharma is Recruiting

AlgiPharma announces two new positions avaliable.

AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. Preference will be given to those candidates already resident in Norway or who are already eligible to work in Norway. The deadline for applications is the 12th May 2019 (see local press advertisement for details on how to submit).

R&D Project Manager

The candidate will proactively manage the day to day running of multiple R&D projects, coordinating with key internal and external stakeholders to advance our portfolio of products for cystic fibrosis, respiratory, wound healing, and other indications based on our alginate oligomer technology. Focused on development of new indications the candidate will develop these project to proof-of-concept (POC) studies in man and cooperate with colleagues and external parties to initiate these studies. The candidate will work collaboratively with a focus on effective planning, coordination of activities, and efficient implementation of R&D strategy. This will include working with external academic and clinical partners, Contract Research Organizations (CROs) and suppliers. The candidate will have demonstrated clear organizational skills and experience of project management in the biotech/biopharma industry, and have relevant experience in R&D and chemical/biotechnological manufacturing. Previous experience establishing effective working relationships in a virtual organization is an asset. The candidate will report directly to the Chief Scientific Officer.

The ideal candidate has:

  • PhD in biological science or a related field.
  • 5+ years’ experience as a Project Manager.
  • Experience in managing multiple project accounts and familiarity applying to funding agencies and reporting on project grants.
  • Experience of project management in the biotechnology or pharmaceutical industry.
  • Proficiency in Microsoft Office programs and tools.
  • Excellent communication and presentation skills in Norwegian and English.

Clinical Trial Manager

We are looking for a well-organized, detail-oriented and flexible candidate to join the clinical team managing the daily operations in the progress of our clinical trials. The candidate will help develop and maintain documentation and materials for clinical trials, working closely with trial sites, and external CRO staff. The candidate will manage multiple aspects of running complex international multicenter trials, including site visits, generate and distribute internal and external reports and newsletters, and liaise with relevant parties regarding all trial aspects. The candidate will play a leading role in generating and overseeing documentation and records, and will work closely with other staff ensuring compliance with relevant guidelines. The candidate will report directly to the Clinical Director.

The ideal candidate has:

  • Bachelor’s degree or higher in biological science, medicine, pharmaceutical, nursing or a related field.
  • 3+ years’ experience as a Clinical Research Associate.
  • Knowledge of pharmaceutical industry, terminology and practices.
  • Knowledge of EU and FDA regulations and their practical implementation.
  • Excellent communication and presentation skills in Norwegian and English.
  • Proficiency in Microsoft Office programs and tools. Experience with commonly used IT tools for clinical trial data collection and analysis.
  • Ability to manage and prioritize workload effectively.
  • Available to travel extensively, and occasionally on short notice.

About AlgiPharma

AlgiPharma AS is dedicated to the development and commercialization of novel therapeutics, based on our patented alginate oligomer technology that will help transform the lives of patients with chronic diseases: Helping patients and their families towards a better day. www.algipharma.com – A better day

AlgiPharma is a clinical stage biopharmaceutical company with a primary focus on respiratory diseases and other conditions caused by microbial infections and biofilms. Our aim is to address unmet medical needs and fight diseases effectively through our innovative alginate technologies. Our alginate technology targets those diseases where there is a clinical need to mitigate abnormal mucus accumulation, microbial infection, biofilm formation and antibiotic resistance. AlgiPharma is developing its first drug candidate for patients with Cystic Fibrosis (CF), where we hold orphan drug status with EMA and FDA. To date we have won about NOK 300 million in Government and NGO support including NOK 120 million from the American Cystic Fibrosis Foundation. We have completed 5 clinical trials to date, and will be initiating 2 more phase 2b multinational trials this spring and summer. The AlgiPharma technology has multiple applications including other respiratory diseases such as COPD, infection, wound healing, and medical device coatings. Building on the success and exciting developments of our technology, the team at AlgiPharma is expanding to meet the demands of bringing our first drug candidate to market.

What we offer:

  • Engaging working environment at a dynamic company on the verge of delivering the first of its drug candidates to market.
  • Opportunity for self-development, such as training courses and/or conferences.
  • A dynamic working atmosphere.
  • Flexibly in working hours to maintain a good work-life balance.
  • Great health insurance plan.
  • Excellent remuneration package, including the opportunity to attend relevant training and education courses and congresses.

New 2b Clinical Trial started in Australia

New Phase 2b Clinical Trial:

A phase 2b, randomised, double-blind, study of alginate oligosaccharide (OligoG) dry powder inhalation on top of standard of care compared to placebo on top of standard of care in patients with Cystic Fibrosis (CF). (ORDCF-205)

A new clinical study was initiated with a Clinical Trial Investigator Meeting held on 29th March alongside the TSANZ conference in Gold Coast, Australia. The clinical trial is a randomised, double-blinded, controlled pilot study for proof of concept that an OligoG dry powder for inhalation formulation can improve lung function in adult CF patients.  Study medication will be given twice daily for twelve weeks on top of standard of care. Thirty-three patients will be included, out of which twenty-two shall receive OligoG, and eleven shall receive placebo. A 12 month open-label extension will be available to all patients who complete the 12 week blinded treatment study.

The study is generously supported by the Cystic Fibrosis Foundation.


 

About Cystic Fibrosis:

Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. The presence or absence of this dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs, which becomes a site for infections that can require hospitalization. Respiratory distress in CF (defined as acute difficulty in breathing, infection and/or hospitalization) is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company with headquarters in Norway. It was founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma Appoints Director for Australian Operations

AlgiPharma has appointed a new director Marieta Ryan to lead the recently established Australian office and to facilitate clinical trial operations in Australia. Marieta was officially appointed in mid-2018 and is actively involved in two of AlgiPharma’s multinational clinical phase 2b studies with clinical sites in Europe, Australia and New Zealand.

About Cystic Fibrosis:

Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. The presence or absence of this dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs, which becomes a site for infections that can require hospitalization. Respiratory distress in CF (defined as acute difficulty in breathing, infection and/or hospitalization) is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company with headquarters in Norway. It was founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

Innovation Award Winner for 2018

AlgiPharma registers new company in Australia

AlgiPharma has registered a new proprietary limited company in Melbourne, Australia:

AlgiPharma Australia Pty Ltd

AlgiPharma is moving ahead with its clinical program and preparations for a new phase 2b clinical trial with its drug candidate OligoG. Australia will be a key part of this pivotal study. The AlgiPharma team recognizes the value in establishing a strong presence in Australia to help bring its lead drug candidate, OligoG, to the market for the treatment of patients suffering with Cystic Fibrosis.

About Cystic Fibrosis:

Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. The presence or absence of this dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs, which becomes a site for infections that can require hospitalization. Respiratory distress in CF (defined as acute difficulty in breathing, infection and/or hospitalization) is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company with headquarters in Norway. It was founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.

AlgiPharma is a privately owned company registered and domiciled in Norway.

 

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

 

AlgiPharma’s Cystic Fibrosis drug candidate OligoG awarded pivotal trial grant of €6 million from EU’s Horizon 2020 programme

An EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.